School of Medicine
Showing 1-20 of 122 Results
Kari Nadeau, MD, PhD
Naddisy Foundation Professor of Pediatric Food Allergy, Immunology and Asthma, Professor of Medicine, of Pediatrics, Senior Fellow at the Woods Institute and Professor, by courtesy, of Otolaryngology and of Epidemiology & Population Health
Current Research and Scholarly InterestsDr. Kari Nadeau’s laboratory and clinical research is focused on understanding the role of genes and the environment, including climate change, on the rising incidence of allergies and asthma. By understanding the genetic, epigenetic, cellular, and humoral factors that mediate immune tolerance or allergy to foods, aeroallegens, and air pollutants (e.g., diesel emissions and wildfires), her research is laying the groundwork for potential future therapies to prevent and cure allergies and asthma.
Clinical Professor, Radiology - Pediatric Radiology
Current Research and Scholarly InterestsClinical research and scholarly interests include topics in Pediatric Nuclear Medicine to include AI evaluation for scintigraphic quantitation, PET MR evaluation of optimized techniques for use in pediatric patient management
Casual - Other Teaching Staff
BioRonjon Nag first became a Stanford Distinguished Careers Institute Fellow in 2016, is currently a Visiting Fellow at the Stanford Center for the Study of Language and Information (CSLI) and teaches popular classes at the intersection of AI healthcare through Stanford Continuing Studies. He is a researcher on the future of intelligence and its impact on society as part of the Stanford Boundaries of Humanity Project (boundariesofhumanity.stanford.edu). He has deployed artificial intelligence systems for mobile devices over three decades, working on neural networks at Cambridge, where he received a PhD in engineering; at Stanford, where he was a Harkness Fellow in the Psychology Department; at MIT, where he received an MS, and at the University of Birmingham, UK where he received a BSc. He received the IET Mountbatten Medal at the Royal Institution for his contributions to the modern mobile phone industry. Companies he has co-founded or advised have been sold to Motorola, BlackBerry, where he held Vice-President positions, and Apple. He is currently an advisor, founder and on the boards of numerous high tech companies including Ecrio, Embee Mobile and GTCardio and he is President of the R42 Institute. Via his company Bounce Imaging where he is chairman, he was winner of the $1m Verizon Powerful Answers Award. He has numerous interests in the intersection of AI and Healthcare including advising companies such as HealX, and Oxford Drug Design on computational drug discovery.
He has many firsts including:
• First laptop with speech recognition built-in (with Apricot, 1984)
• First selling cursive handwriting recognition (with Lexicus, 1991)
• First speech recognition phones (with Lexicus/Motorola, 1996)
• First large-vocabulary Chinese speech recognition (with Lexicus/Motorola, 1996)
• First Chinese predictive text system on a phone (Lexicus/Motorola, 1997)
• First predictive text systems in 40 languages on Motorola phones, (Lexicus/Motorola, 1997)
• First touch screen mobile phone with handwriting recognition (Lexicus/Motorola, 1999)
• First combined mobile search engine and directory (with Cellmania, 2000)
• First private label downloadable operator billable apps store (Cellmania, 2000)
• First BlackBerry Operator Billing apps store (Cellmania,2010)
• First Neural Network Artificial Intelligence System in the Cloud (Ersatz Labs, 2014)
• First Throwable 360 Ball Camera (Bounce Imaging, 2015)
• First Android powered smart light switch (Brightswitch 2017)
• First blood pressure watch with temperature and pulse oximetry add-ons for Back to Work Covid Kit (GTCardio 2019)
Claude M. Nagamine, DVM, PhD
Associate Professor of Comparative Medicine
Current Research and Scholarly InterestsMouse models to study murine and human infectious diseases. These colloborative studies include dengue virus, zika virus, adeno-associated virus, coxsackie virus, enterovirus 71, enterohepatic helicobacters, campylobacters, and anaplasma.
Seema Nagpal, MD
Clinical Associate Professor, Neurology & Neurological Sciences
Clinical Associate Professor (By courtesy), Neurosurgery
Current Research and Scholarly InterestsI'm a board certified neuro-oncologist who treats both primary brain tumors as well as metastatic disease to the brain and nervous system. My research concentrates on clinical trials for patients with late-stage central nervous system cancer. I have a special interest in leptomeningeal disease, a devastating complication of lung and breast cancers. I collaborate with Stanford scientists to detect this disease earlier, and with our breast and lung oncologists to improve outcomes for patients.
Hiromitsu (Hiro) Nakauchi
Professor of Genetics (Stem Cell)On Leave from 10/01/2022 To 01/31/2023
Current Research and Scholarly InterestsTranslation of discoveries in basic research into practical medical applications
Instructor, Stanford Cancer Institute
Current Research and Scholarly InterestsFrom 2005 to 2010, my work as a clinical hematology fellow allowed me to experience first-hand how scientific advances that started in a laboratory can transform the lives of patients. While many of my patients were cured of their disease with allogeneic hematopoietic stem cell transplantation, underscoring the importance of anti-tumor immunotherapy in eradicating leukemia, I witnessed face-to-face their suffering from the long-term consequence of graft-versus-host disease (GVHD). This experience was ultimately what drove me to engage in research to discover novel therapies. For this reason, I embarked on a PhD program in 2010 to design antibody therapy to (i) target GVHD and (ii) target hematological malignancies. Under the mentorship of Professor Hiromitsu Nakauchi at the University of Tokyo, an international leader in hematopoiesis, I developed allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies for severe GVHD caused by HLA-mismatched hematopoietic stem cell transplantation (Nakauchi et al., Exp Hematol, 2015). This study was the first to find that anti-HLA antibodies can be used therapeutically against GVHD. That success gave me the motivation and confidence to further my research beyond targeting GVHD, to targeting leukemic stem cells through my current postdoctoral fellowship in the laboratory of Professor Ravindra Majeti, Department of Hematology at Stanford University.
Many people suffer from leukemia each year, but we still don’t know how to completely cure it. Recent advances in sequencing technologies have tremendously improved our understanding of the underlying mutations that drive hematologic malignancies, although, the reality is that the majority of the mutations are not easily “druggable” and the discovery of these mutations has not yet made a significant impact in patient outcomes. I view this perhaps the most crucial challenges facing a translational cancer researcher like myself. My current research is a major step toward my long term goal to make personalized medicine a reality for patients with acute myeloid leukemia (AML) and other hematologic malignancies. Although my research is focused on targeting Ten-Eleven Translocation methylcytosine dioxygenase-2 (TET2) mutations, I anticipate it will lead to a better understanding of the cell context requirement for TET2 mutations in AML and help identify the critical cells to target to both prevent the development of de novo leukemia and halt relapse. It may also prove of value to understanding of the biology of a range of other cancers.
Shweta S. Namjoshi MD MPH CNSC
Clinical Assistant Professor, Pediatrics - Gastroenterology
Current Research and Scholarly Interests1. The mission of the International Intestinal Failure Registry (IIFR) is to provide the international intestinal rehabilitation and transplant community with accurate data on the outcomes and course of intestinal failure to support research, quality improvement, and policy development. https://tts.org/irta-registries/irta-ifr
2. NCT05241444 is the first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.
3. Stanford's local Intestinal Failure Registry (SIFR) ensures ongoing assessment and improvement of intestinal failure outcomes and care provided at Stanford in collaboratiton with the Division of Pediatric Surgery. This registry focuses on clinical outcomes and social developmental outcomes for patients with short bowel syndrome, pediatric CODEs, and pseudoobstruction.
4. Multiple, multicenter projects with NASPGHAN (https://naspghan.org/) Nutrition Committee's and the NASPGHAN Intestinal Rehabilitation Special Interest Group ensure assessment of blenderized tube feeding, iron in intestinal failure, and other multicenter research.
5. Through the Office of Child Health Equity, I collaborate with the subgroup focusing on equity analytics & community based participatory research as assistant director of health policy to advocate for communities and a world where healthcare and life outcomes are equitable and just. My interests include civic health & disability justice.